TCP
TEVA icon

Tourbillon Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Tourbillon Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,736,000
Closed -$42.2M – 70
2018
Q2 		$42.2M Buy
+1,736,000
New +$35.4M 1.63% 18

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Tourbillon Capital Partners's TEVA Position: Q4 2016 in Review

Tourbillon Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 290,000 shares — an estimated $13.3M sold.

Tourbillon Capital Partners first reported a position in TEVA in Q2 2015 and held it in 3 quarters. The position peaked at $97.5M in Q2 2015. 738 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • Tourbillon Capital Partners reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Tourbillon Capital Partners sold 290,000 Teva Pharmaceuticals shares in Q4 2016, an estimated $13.3M.
  • Tourbillon Capital Partners first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 3 quarters.
  • Tourbillon Capital Partners's Teva Pharmaceuticals position peaked at $97.5M in Q2 2015.
  • 738 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Tourbillon Capital Partners's 13F filing for Q4 2016, filed 14 Feb 2017.